What is MeiraGTx Holdings plc's market cap?

MeiraGTx Holdings plc (MGTX) has a market capitalization of $1.3B and trades on NASDAQ.

What is MeiraGTx Holdings plc's revenue and profitability?

MeiraGTx Holdings plc generated $79.8M in trailing twelve-month revenue with a net loss of $175.6M, representing a net margin of -615.3%, with free cash flow of -$80.7M. These figures are based on the Q1 2026 filing.

Who are MeiraGTx Holdings plc's competitors?

MeiraGTx Holdings plc's key competitors include Regeneron Pharmaceuticals, Voyager Therapeutics, REGENXBIO Inc., and others. These companies compete in similar markets and product categories.

Who does MeiraGTx Holdings plc partner with?

MeiraGTx Holdings plc's notable partners include Johnson & Johnson.

What subsidiaries does MeiraGTx Holdings plc have?

MeiraGTx Holdings plc's subsidiaries include MeiraGTx UK.

Where is MeiraGTx Holdings plc headquartered?

MeiraGTx Holdings plc is headquartered in United States of America and employs approximately 402 people. It has been publicly traded since 2018.

MeiraGTx Holdings plc

MGTX

MeiraGTx is a vertically integrated, clinical-stage biotechnology company focused on developing genetic medicines for both inherited and common diseases.

Market cap

$1.29B+86.4%

Revenue$79.8M+131%

Net income-$175.6M-18.8%

Free cash flow-$80.7M+26.2%

EPS (diluted)-$2.18-2.4%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$293.0KMiss by $16.7M EPS-$0.57Beat by $0.04

Read the full report

Next report

Aug 13, 2026 (in a month)

Revenue estimate$700.0K

EPS estimate-$0.33

Financials

Q1 2026

Income statement

See full

Revenue$293.0K-84.8%

Operating income-$40.8M+1.9%

Net income-$46.3M-15.8%

EPS (diluted)-$0.57-11.8%

Balance sheet

See full

Cash & equivalents$71.5M+7.5%

Total debt$62.7M-22.5%

Total equity-$58.1M-276%

Total assets$244.7M+9.2%

Cash flow

See full

Operating cash flow$17.8M+148%

CapEx$2.0M+17.4%

Free cash flow$15.8M+141%

Valuation & ratios

Valuation

See full

Market cap$1.29B+86.4%

Enterprise value$1.28B+91.3%

P/S16.2×-0.2×

Returns & leverage

See full

Current ratio0.5×-1.0×

Segments

By product

See full

Related Party Service Revenue$293.0K-84.8%

Competitors

By market cap

Regeneron Pharmaceuticals$70.0B+20.5%

Relay Therapeutics, Inc.$4.5B+643%

MeiraGTx Holdings plc$1.3B+108%

Regenxbio$809.1M+90.5%

Prime Medicine$764.0M—

Voyager Therapeutics, Inc.$222.4M+32.2%

Aldeyra Therapeutics$138.7M-46.8%

Metagenomi Therapeutics, Inc. $47.4M-24.9%

By revenue growth

MeiraGTx Holdings plc+131%

Relay Therapeutics, Inc.+39.0%

Regeneron Pharmaceuticals+5.9%

Regenxbio-44.0%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

Regenxbio-330.23%-230pp

MeiraGTx Holdings plc-615.27%+208pp

Relay Therapeutics, Inc.-2,554.14%+1,787pp

Prime Medicine-4,342.44%—

Profile

MeiraGTx is a vertically integrated, clinical-stage biotechnology company focused on developing genetic medicines for both inherited and common diseases. The company leverages a proprietary end-to-end manufacturing platform and a transformative synthetic riboswitch technology to enable precise, dose-responsive gene regulation via oral small molecules.

Competitive position

A vertically integrated player with internal commercial-scale manufacturing and a unique synthetic riboswitch platform for dose-responsive gene expression.

GeographiesUnited Kingdom, Ireland, United States

Customer segmentsPatients, Biopharmaceutical Companies

Business modelR&D, Manufacturing, Licensing

SuppliersRaw material suppliers, Laboratory equipment providers, Clinical trial sites

CustomersSpecialty pharmacies, Hospitals, Biopharmaceutical licensing partners

CountryUnited States of America

Listed2018

Employees402.0

CEOAlexandria Forbes

SectorHealthcare

IndustryBiotechnology

Websitemeiragtx.com

FilingsSEC EDGAR

Ask your AI about MeiraGTx Holdings plc.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MeiraGTx Holdings plc's market cap?: MeiraGTx Holdings plc (MGTX) has a market capitalization of $1.3B and trades on NASDAQ.
What is MeiraGTx Holdings plc's revenue and profitability?: MeiraGTx Holdings plc generated $79.8M in trailing twelve-month revenue with a net loss of $175.6M, representing a net margin of -615.3%, with free cash flow of -$80.7M. These figures are based on the Q1 2026 filing.
Who are MeiraGTx Holdings plc's competitors?: MeiraGTx Holdings plc's key competitors include Regeneron Pharmaceuticals, Voyager Therapeutics, REGENXBIO Inc., and others. These companies compete in similar markets and product categories.
Who does MeiraGTx Holdings plc partner with?: MeiraGTx Holdings plc's notable partners include Johnson & Johnson.
What subsidiaries does MeiraGTx Holdings plc have?: MeiraGTx Holdings plc's subsidiaries include MeiraGTx UK.
Where is MeiraGTx Holdings plc headquartered?: MeiraGTx Holdings plc is headquartered in United States of America and employs approximately 402 people. It has been publicly traded since 2018.